VBI Vaccines Inc.

NASDAQ:VBIV  
3.89
-0.06 (-1.52%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)981.30M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.48 Million
Adjusted EPS-$0.07
See more estimates
10-Day MA$3.86
50-Day MA$3.19
200-Day MA$3.14
See more pivots

VBI Vaccines Inc. Stock, NASDAQ:VBIV

222 3rd Street, Suite 2241, Cambridge, Massachusetts 02142
Phone: +1.617.830.3031
Number of Employees: 127

Description

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.